Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Therapeuticsmd Inc (NQ: TXMD )

4.400 +0.250 (+6.02%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 2, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 24,007
Open 4.020
Bid (Size) 4.110 (1)
Ask (Size) 4.410 (16)
Prev. Close 4.150
Today's Range 4.020 - 4.430
52wk Range 3.250 - 11.69
Shares Outstanding 9,953,290
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
TherapeuticsMD Announces First Quarter 2023 Financial Results
From TherapeuticsMD, Inc.
Via Business Wire
TherapeuticsMD Announces Full Year 2022 Financial Results and Provides Update on Business Model Transition
From TherapeuticsMD, Inc.
Via Business Wire

Performance

YTD
-29.60%
-29.60%
1 Month
+8.64%
+8.64%
3 Month
-7.37%
-7.37%
6 Month
-14.06%
-14.06%
1 Year
-55.69%
-55.69%

More News

Read More
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
Via InvestorPlace
TherapeuticsMD Completes Transaction to License Its Products to Mayne Pharma
From TherapeuticsMD, Inc.
Via Business Wire
Why TherapeuticsMD Stock Is Trading Higher
Via Benzinga
TherapeuticsMD: Q2 Earnings Insights
Via Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
TherapeuticsMD Announces Definitive Agreements to License its Products to Mayne Pharma
From TherapeuticsMD, Inc.
Via Business Wire
TherapeuticsMD Announces Third Quarter 2022 Financial Results
From TherapeuticsMD, Inc.
Via Business Wire
TherapeuticsMD Announces Additional $7 Million Private Placement
From TherapeuticsMD, Inc.
Via Business Wire
TherapeuticsMD Announces $7 Million Private Placement
From TherapeuticsMD, Inc.
Via Business Wire
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
TherapeuticsMD Appoints Dr. Brian Bernick and Mr. Mark Glickman as Interim Co-Chief Executive Officers
From TherapeuticsMD, Inc.
Via Business Wire
Looking Into TherapeuticsMD's Return On Capital Employed
Via Benzinga
Why Allena Pharmaceuticals Tumbled Over 30%; Here Are 85 Biggest Movers From Yesterday
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
Snap, Gilead Sciences And Some Other Big Stocks Moving Higher On Monday
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
TherapeuticsMD Announces Second Quarter 2022 Financial Results
From TherapeuticsMD, Inc.
Via Business Wire
Why Viridian Therapeutics Is Trading Higher By Around 58%, Here Are 67 Stocks Moving In Monday's Mid-Day Session
Via Benzinga
TherapeuticsMD Earnings Preview
Via Benzinga
Earnings Scheduled For August 15, 2022
Via Benzinga
TherapeuticsMD to Report Second Quarter 2022 Financial Results on August 15, 2022
From TherapeuticsMD, Inc.
Via Business Wire
$15 Million Bet On This Healthcare Stock? 3 Stocks Insiders Are Buying
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.